CHMP recommends MenQuadfi for prophylaxis against invasive meningococcal disease .- Sanofi Pasteur

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product MenQuadfi, intended for prophylaxis against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y. The applicant for this medicinal product is Sanofi Pasteur. MenQuadfi will be available as a solution for injection. The active substance of MenQuadfi is a conjugate of meningococcal group A, C, W and Y capsular polysaccharides with tetanus toxoid as carrier protein, forming a meningococcal vaccine (ATC code: J07AH08) that stimulates the production of antibodies specific to those capsular polysaccharides. The anti-capsular antibodies protect against meningococcal disease via complement-mediated bactericidal activity. The benefits with MenQuadfi are its ability to prevent invasive disease caused by Neisseria meningitidis groups A, C, W and Y in individuals aged 12 months and older. The most common side effects are injection site reactions such as erythema, swelling and pain.